Abstract
This study was for verifying that transfecting colon cancer cells (CCCs) with lncRNA NEAT1 packed with siRNA chitosan nanoparticles (CNPs) can suppress lncRNA NEAT1 and biological behaviors of the cells. siRNA targeting lncRNA NEAT1 expression vector was constructed and then transfected into CCCs after being packed with CNPs. Subsequently, the impact of the transfection on biological behaviors of the cells was evaluated. As a result, with high expression in CCCs, NEAT1 was negatively bound up with miR-377-3p in cases with colon cancer (CC), and dual luciferase reporter assay confirmed the potential binding region. Additionally, after downregulating NEAT1 in CCCs, transfection of NEAT1 siRNA packed with CNPs brought a great inhibition on cell proliferation and a promotion on apoptosis, and inhibiting miR-377-3p was able to offset the role of silencing NEAT1 in CCCs. Therefore, in our opinion, NEAT1 siRNA packed with CNPs can hinder the growth and metastasis of CCCs by knocking down NEAT1 in CC, and its mechanism may be achieved by targeting miR-377-3p, which offers a novel direction for treating CC.
Highlights
With an increasingly high global prevalence and mortality, colon cancer (CC) poses a grave threat to human life and health [1, 2]
Small interfering RNA is a short double-stranded RNA that can achieve sequence-specific gene silencing of complementary mRNA, induce mRNA degradation, and inhibit the production of target proteins [6, 7]. siRNA has shown potential as a molecular means to downregulate the expression of specific genes in cancer cells [8]
The results indicate the effective transfection of nano-NEAT1-siRNA packed with chitosan nanocarrier for CC
Summary
With an increasingly high global prevalence and mortality, colon cancer (CC) poses a grave threat to human life and health [1, 2]. It is mainly treated via conventional means like surgery combined with chemoradiotherapy, but after such treatment, patients still show a high recurrence rate and incidence of adverse reactions and face unfavorable prognosis [3, 4]. SiRNA has shown potential as a molecular means to downregulate the expression of specific genes in cancer cells [8]. The siRNA-based therapies have emerged as a promising strategy for targeting a variety of diseases [10]. It is imperative to develop a safe and effective delivery system for siRNA
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
